 |
 |
I spoke today with Craig Smith, CEO of Guilford Pharmaceuticals, and got a quick update on the progress of the NIL-A development. The process of transfer of data from Amgen is almost complete and the IND (investigational new drug) has been assigned to Guilford at the FDA, but substantial work to remains to get all the 300 contracts with vendors and investigators reassigned to Guilford. A contract research organization is being hired to conduct additional analyses. Guilford is establishing a small group of three patient advisors for the study, including me and two others. Similarly they have established a executive committee of Physicians who participated in the trial to guide interactions with the physicians. They are anxious to get input from participants in the trial, but before they unblind what medication each subject was on, they want to send a questionnaire to all participants to try to document the full range of effects experienced by each, including especially non-motor effects on mood, cognition, autonomic system problems, etc. After the end of the year they hope to be in a position to hold a meeting for phase II participants where they would share the analyses of Phase II data and get feedback. Perry Cohen www.parkinsonscare.org ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn